Australian biotechnology company CSL Ltd (ASX:CSL) has said that it is committed to its agreement for the production of about 50 million doses of British pharmaceutical company AstraZeneca's (LON:AZN) COVID-19 vaccine into 2022, Reuters news agency reported on Thursday.
This follows a media report that AstraZeneca's Vaxzevria vaccine would no longer be manufactured in Australia due to demand for vaccines of Pfizer (NYSE:PFE) and Moderna (Nasdaq:MRNA).
CSL stated that over 20 million doses of the vaccine have already been produced and it is expected that the remaining production will be completed early next year.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine